Drugs / SNB-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04640480 | Oct 2020 → Jan 2026 | breast cancer, colorectal cancer, gastric cancer, head and neck cancer +3 | SN BioScience | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04640480 ↗ |
| Modality | Other / unclassified | “SNB-101 is a novel nano-particle formulation of SN-38” NCT04640480 ↗ |
| Route | Intravenous | “SNB-101 will be administered intravenously to participants” NCT04640480 ↗ |